Remove Applications Remove Guidelines Remove Pharmaceuticals Remove Software
article thumbnail

Amid COVID-19 pandemic, experts lay out 10-point plan for a genomic revolution in public health

GeekWire

” Another challenge relates to the software that’s been created to analyze genomic data for epidemiological purposes. Strengthen application programming interfaces. Develop guidelines for management and stewardship of genomic data. Make bioinformatics pipelines fully open-sources and broadly accessible.

Research 145
article thumbnail

6 Steps in Enterprise 2.0 Governance Projects

Trends in the Living Networks

Governance, done well, is an enabler of innovation, providing parameters, guidelines and policies that address risks, and allow the greatest possible scope for experimentation and value creation. tools, in particular addressing the applications already suggested by group across the organization. Set IT strategies and guidelines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Here are all the winners of the 2020 Webby Awards

The Verge

Webby Award for Web Services & Applications : Paste by WeTransfer. Webby People’s Voice Award for Web Services & Applications : Streamtime. Best Visual Design – Function : Material Design— Dark Theme Guidelines & Article by Google; Portal - Focus, Sleep, Escape by Portal Labs Ltd. Collective.

Film 95
article thumbnail

Generative AI sparks a drug discovery renaissance

Dataconomy

First, AI makes the drug sector a more profitable industry In this blog post, we will delve into the details of how generative AI is shaping the landscape of drug discovery, its applications, and the challenges it faces. De novo drug design : One of the most exciting applications of generative AI in drug discovery is de novo drug design.

article thumbnail

The AI rules that US policymakers are considering, explained

Vox

Licensing requirements : The attorney Andrew Tutt in 2017 proposed a more far-reaching approach than simply mandating risk evaluations, one instead modeled on tougher US regulations of food and pharmaceuticals. The Food and Drug Administration generally does not allow drugs on the market that have not been tested for safety and effectiveness.